INTRODUCTION:

Cancer, a complex and relentless group of diseases, continues to pose a profound global health challenge. Despite significant advancements in our understanding of its molecular underpinnings and the development of various therapeutic modalities, the quest for effective and less toxic cancer treatments remains a high priority. One promising avenue that has gained increasing attention in recent years is the therapeutic targeting of free radicals¹.

Cancer is characterized by uncontrolled cell growth and the ability to evade the body's natural defense mechanisms. Central to the cancer puzzle is the role of reactive species (ROS) and free radicals, highly reactive molecules that are normally generated as byproducts of cellular metabolism. Historically, ROS have been viewed as culprits in DNA damage and cellular dysfunction, contributing to the initiation and progression of cancer. However, emerging research has unveiled a nuanced and multifaceted relationship between free radicals and malignancy².

Cancer, a formidable adversary in the realm of human health, continues to challenge our understanding of disease and our capacity to combat it effectively. For decades, scientists have diligently sought to unravel the mysteries of cancer development and progression, probing deep into the intricate biochemical and genetic landscapes that define this diverse group of diseases. In this journey of exploration, one phenomenon has emerged as a key player in the intricate drama of carcinogenesis—free radicals^2,3.

Reactive oxygen species (ROS) and free radicals are highly reactive molecules that are, by nature, both essential and destructive. Within the healthy confines of cellular metabolism, they serve as crucial signaling molecules, participating in fundamental processes such as cell growth, immune response, and cellular defense mechanisms. However, their Janus-faced nature becomes evident when their production spirals out of control, leading to oxidative stress and cellular damage⁴.

It is this duality that sets the stage for our exploration into the relationship between free radicals and cancer. This article delves deep into the complex and often paradoxical role of ROS in cancer biology, uncovering their involvement in both the initiation and progression of malignancy. While the concept of free radicals as cancer instigators may seem paradoxical at first glance, it becomes increasingly clear that their contribution to tumorigenesis is a multifaceted and context-dependent phenomenon^3,4.

1. The role of free radicals in cancer biology:

Cancer, often characterized as a complex and multifaceted disease, has been the subject of intense scrutiny by scientists and clinicians alike. Understanding the intricate mechanisms driving cancer initiation and progression is pivotal for the development of effective therapeutic strategies. Among the multitude of factors influencing carcinogenesis, one has emerged as a significant player in recent years—reactive oxygen species (ROS) and their free radical counterparts⁴.

1.1 Sources and Mechanisms of Free Radical Generation:

At the heart of the relationship between free radicals and cancer lies the production and regulation of these highly reactive molecular species. Free radicals, such as superoxide anion (O2•−), hydroxyl radical (•OH), and nitric oxide (•NO), are formed as natural byproducts of cellular metabolism. Key sources of free radical generation include mitochondria, the endoplasmic reticulum, and various enzymatic reactions within the cell.

The delicate balance between free radical production and the antioxidant defense system is paramount. Under normal physiological conditions, cells maintain a redox equilibrium, ensuring that free radicals serve as crucial signaling molecules while avoiding excessive oxidative stress. However, perturbations in this balance can tip the scales toward oxidative damage, a hallmark feature of cancer^4,5.

1.2 Free radicals in cellular signaling pathways:

Beyond their role as destructive entities, free radicals actively participate in cellular signaling pathways, exerting influence over fundamental processes like cell growth, differentiation, and immune responses. In the context of cancer biology, these signaling roles are of particular interest, as they can contribute to tumor initiation and progression.

Free radicals modulate cellular responses by interacting with key biomolecules, including proteins, lipids, and DNA. These interactions lead to post-translational modifications, gene expression changes, and alterations in cellular behavior. Thus, free radicals have the potential to promote oncogenic signaling, enabling cancer cells to evade apoptosis, stimulate angiogenesis, and enhance their invasive capabilities⁷.

1.3 Oxidative stress and cancer development:

Oxidative stress, characterized by an imbalance between the production of free radicals and the cellular antioxidant defenses, emerges as a central theme in cancer development. Excessive ROS production, often driven by oncogenic mutations or environmental factors, can inflict widespread cellular damage.

One of the critical consequences of oxidative stress is the damage to genomic DNA. ROS-induced DNA lesions, such as base modifications and strand breaks, contribute to genomic instability—a hallmark of cancer. This instability can lead to the accumulation of mutations, providing the genetic diversity that fuels tumor heterogeneity and evolution.

Additionally, oxidative stress influences the tumor microenvironment, promoting chronic inflammation and fostering conditions conducive to tumor growth. It also contributes to resistance against conventional cancer therapies, further underscoring its significance in the cancer paradigm.

In the following subsections, we will explore the nuanced interplay between free radicals and cancer biology, emphasizing their roles as both instigators of malignancy and potential targets for therapeutic intervention^8,9.

2. The dual nature of free radicals in cancer:

The relationship between free radicals and cancer is far from one-dimensional. While it is evident that excessive oxidative stress and free radical generation can contribute to cellular damage and cancer development, a closer examination reveals a paradoxical duality in their roles within the oncogenic landscape. This section delves into the multifaceted nature of free radicals in the context of cancer biology, emphasizing their capacity to both promote carcinogenesis and offer vulnerabilities that can be exploited for therapeutic benefit¹⁰.

2.1 Pro-carcinogenic effects of free radicals:

At first glance, free radicals might appear solely as culprits in the complex narrative of cancer. Their propensity to induce DNA damage, modify critical biomolecules, and disrupt cellular homeostasis is unquestionably detrimental. This pro-carcinogenic aspect is particularly evident in instances where oxidative stress is persistent, resulting in a chronic state of cellular damage and inflammation ¹¹.

In this section, we will explore the ways in which free radicals actively contribute to cancer initiation and progression. This includes their involvement in genetic mutations, the promotion of oncogenic signaling pathways, and the creation of a tumor-permissive microenvironment. By understanding these pro-carcinogenic effects, we can appreciate the significance of controlling free radical levels in the context of cancer therapy¹².

2.2 Redox vulnerabilities in cancer cells:

However, a deeper analysis reveals a counterintuitive aspect of free radicals: the vulnerability they introduce to cancer cells. While these molecules are capable of instigating oncogenic processes, they also impose redox stress on cancer cells that can be leveraged to therapeutic advantage. This paradoxical vulnerability arises due to the increased reliance of cancer cells on pro-oxidant processes for survival and proliferation.

Cancer cells, driven by their uncontrolled growth and rapid metabolism, often generate higher levels of ROS compared to their non-cancerous counterparts. This heightened oxidative stress creates a unique susceptibility within cancer cells that can be exploited by targeted therapies. In this section, we will explore how the very processes that drive cancer progression also provide an Achilles' heel—a vulnerability that can be selectively targeted to undermine cancer cell survival and growth.

As we navigate the intricate interplay between free radicals and cancer in the sections that follow, it becomes evident that a nuanced understanding of their dual nature is crucial for the development of novel therapeutic strategies. By embracing this complexity, we can unlock the potential to harness free radicals as both adversaries and allies in the ongoing battle against cancer ^13,14.

3. Current strategies for targeting free radicals in cancer:

As our understanding of the intricate relationship between free radicals and cancer biology deepens, so does our ability to leverage this knowledge for therapeutic benefit. The recognition of free radicals as both instigators of malignancy and vulnerabilities within cancer cells has paved the way for innovative approaches to cancer treatment. In this section, we explore the current strategies employed to target free radicals as a means of curbing cancer progression and enhancing therapeutic outcomes⁴.

3.1 The role of antioxidants:

One of the most intuitive approaches to mitigating the pro-carcinogenic effects of free radicals is the use of antioxidants. These molecules act as scavengers, neutralizing excessive reactive oxygen species (ROS) and preventing oxidative damage to cellular components. Antioxidants, both endogenous and exogenous, play a vital role in maintaining redox balance within healthy cells¹⁵.

In this subsection, we delve into the rationale behind antioxidant therapy and its potential applications in cancer treatment. We explore the mechanisms by which antioxidants counteract oxidative stress and discuss the challenges and complexities associated with achieving the right balance between ROS modulation and cancer cell elimination ^16,9.

3.2 Radiation therapy and ROS:

Radiation therapy, a cornerstone of cancer treatment, capitalizes on the pro-oxidant properties of ionizing radiation to induce DNA damage within cancer cells. The generation of ROS as a consequence of radiation exposure plays a central role in this therapeutic modality. Radiation-induced oxidative stress triggers a cascade of events leading to cancer cell death¹⁷.

This subsection explores the intricate interplay between radiation therapy and ROS generation, highlighting the mechanisms by which radiation provokes oxidative damage within cancer cells. We also discuss the clinical applications of radiation therapy, its efficacy in different cancer types, and potential strategies to enhance its selective targeting of cancer cells^18,19.

3.3 Chemotherapy and redox vulnerabilities:

Chemotherapy, a widely utilized cancer treatment, has also been harnessed to exploit the redox vulnerabilities inherent in cancer cells. Certain chemotherapeutic agents directly target cellular processes that rely on redox balance for survival. These agents disrupt the delicate equilibrium of ROS in cancer cells, leading to oxidative stress and apoptosis^20,21.

In this subsection, we explore the principles behind chemotherapy-induced redox vulnerabilities in cancer cells. We discuss specific chemotherapeutic agents and their mechanisms of action, emphasizing their capacity to selectively target cancer cells while sparing normal tissue. Furthermore, we address challenges associated with chemotherapy, such as drug resistance and side effects, and the ongoing efforts to enhance its efficacy.

As we examine these current strategies for targeting free radicals in cancer therapy, it becomes apparent that a multifaceted approach is essential. The complex nature of cancer necessitates a comprehensive understanding of the interplay between free radicals and therapeutic interventions. By unraveling these intricacies, we can optimize existing strategies and pave the way for the development of innovative, targeted approaches to cancer treatment^22,14.

4. Future directions in free radical-based cancer therapy:

The landscape of cancer therapy is continually evolving, driven by advances in science and a deeper understanding of the complexities of the disease. In the pursuit of more effective and precise treatments, researchers are exploring novel strategies that harness the potential of free radicals. This section embarks on a journey into uncharted territories of research, delving into cutting-edge approaches that represent the future of free radical-based cancer therapy¹⁸.

4.1 Nanotechnology in free radical modulation:

Nanotechnology offers a promising frontier for fine-tuned control over free radicals within cancer cells. Nanoparticles designed to deliver specific payloads can be engineered to target and modulate the redox environment within tumors. This precision allows for the localized generation or scavenging of free radicals, minimizing off-target effects on healthy tissue.

In this subsection, we delve into the exciting world of nanotechnology-driven interventions. We explore the design principles of nanoparticle-based therapies, their potential applications in different cancer types, and the challenges associated with their clinical translation. The intersection of nanotechnology and free radical modulation opens doors to therapies that combine precision with efficacy^23,24.

4.2 Gene therapy approaches:

Advancements in gene therapy are reshaping the landscape of cancer treatment. The manipulation of gene expression to modulate cellular responses to oxidative stress presents a novel avenue for cancer therapy. Gene therapy strategies can be tailored to enhance antioxidant defenses within normal tissue while sensitizing cancer cells to oxidative damage ²⁵.

This subsection delves into the realm of gene therapy approaches that leverage ROS modulation. We discuss the design of therapeutic vectors, the identification of target genes, and the potential for combinatorial therapies that synergize with existing treatments. Gene therapy offers the promise of personalized interventions that exploit the redox vulnerabilities of individual cancers²⁶.

4.3 Immunomodulatory strategies:

The immune system's role in cancer surveillance and control is well-established. Emerging immunomodulatory strategies seek to harness the power of the immune system to target malignant cells. In this context, free radicals can serve as essential mediators of immune responses, influencing both tumor-promoting inflammation and antitumor immunity.

This subsection explores the intersection of immunology and free radical-based cancer therapy. We discuss approaches that aim to modulate immune responses through the manipulation of ROS and the promotion of immune-mediated tumor cell killing. From immune checkpoint inhibitors to adoptive cell therapies, these strategies highlight the potential to turn the immune system into a potent weapon against cancer.

As we embark on this exploration of future directions in free radical-based cancer therapy, it becomes evident that innovation is key to advancing the field. The convergence of cutting-edge technologies, such as nanotechnology and gene therapy, with a deeper understanding of the redox biology of cancer offers hope for more precise, effective, and personalized treatments. These approaches represent the future of cancer therapy, where the potential of free radicals is harnessed in ways previously unimagined^27,28.

5. Biomarkers and personalized approaches:

The journey towards more effective cancer therapies is increasingly marked by the quest for precision and individualization. In this section, we turn our attention to the pivotal role of biomarkers and personalized approaches in the context of free radical-based cancer therapy. Understanding the unique redox profiles of patients and their tumors is becoming essential for tailoring treatments that maximize efficacy while minimizing harm²⁹.

5.1 Importance of Biomarkers:

Biomarkers are molecular or cellular indicators that provide valuable information about the state of a patient's health or disease. In the realm of cancer therapy, biomarkers have emerged as critical tools for characterizing the redox status of tumors and predicting their response to treatment. By deciphering the intricacies of each patient's oxidative stress landscape, clinicians can make informed decisions about therapy selection and monitoring.

In this subsection, we explore the significance of biomarkers in the context of free radical-based cancer therapy. We discuss the various types of biomarkers, including genetic, proteomic, and imaging-based markers, and their utility in assessing oxidative stress levels in tumors. The integration of biomarker information into treatment decisions is a crucial step towards personalized cancer care^29,30,31.

5.2 Monitoring oxidative stress:

Effective personalized cancer therapy relies not only on the identification of relevant biomarkers but also on real-time monitoring of oxidative stress during treatment. Continuous assessment of redox dynamics enables clinicians to adapt therapies as needed, optimizing outcomes and minimizing toxicity.

This subsection delves into the methods and technologies employed for monitoring oxidative stress in cancer patients. From non-invasive imaging techniques to minimally invasive blood tests, we explore the tools available for assessing the redox status of tumors and surrounding tissues. Timely and accurate monitoring ensures that therapeutic interventions are adjusted in response to dynamic changes in oxidative stress, aligning treatment with the evolving needs of the patient^8,9.

5.3 Personalized treatment strategies:

The era of personalized cancer treatment is characterized by a shift away from one-size-fits-all approaches. Instead, therapies are tailored to the unique molecular and redox profiles of individual patients and their tumors. Personalized treatment strategies hold the promise of higher response rates, fewer side effects, and improved patient outcomes.

In this subsection, we examine the principles underlying personalized treatment strategies in free radical-based cancer therapy. We discuss how biomarker data inform treatment selection, dosing, and scheduling. We also explore the potential for combination therapies that leverage a patient's specific redox vulnerabilities. By aligning treatments with the patient's biological intricacies, personalized approaches represent the pinnacle of precision medicine in oncology ³².

As we navigate the complexities of biomarkers and personalized approaches in the context of free radical-based cancer therapy, it becomes evident that the future of cancer care is characterized by individualized precision. The integration of biomarker information and real-time monitoring empowers clinicians to make data-driven decisions, ensuring that each patient receives a treatment regimen optimized for their unique biology. In doing so, we embark on a path towards more effective, less toxic, and truly patient-centered cancer therapy^32,33.

6. Clinical applications and case studies:

As scientific insights and innovative strategies for free radical-based cancer therapy continue to evolve, it is essential to bridge the gap between laboratory discoveries and real-world patient care. This section provides a comprehensive view of the clinical applications of free radical-based therapies and offers illuminating case studies that underscore their practical relevance, challenges, and potential for transforming cancer treatment.

6.1 Real-world applications of free radical-based therapies:

The translation of scientific discoveries into clinical practice is a critical milestone in the development of cancer therapies. In this subsection, we explore the tangible applications of free radical-based therapies in the clinical setting. From antioxidants as adjuvants in conventional treatments to radiation therapy and chemotherapy strategies that exploit redox vulnerabilities, we delve into the impact of these therapies on patient outcomes.

We discuss clinical trials and real-world experiences that shed light on the efficacy and safety profiles of free radical-based therapies in various cancer types. The integration of these therapies into standard treatment protocols reflects the ongoing effort to enhance cancer care by leveraging the intricacies of oxidative stress and redox biology^33,34.

6.2 Clinical trials and efficacy:

The path from laboratory research to clinical practice often passes through rigorous clinical trials. In this subsection, we delve into the landscape of clinical trials that investigate free radical-based therapies for cancer. We examine the methodologies, endpoints, and outcomes of these trials, offering insights into the therapeutic potential and challenges associated with these approaches.

By exploring the results of clinical trials, we gain a deeper understanding of the evidence supporting free radical-based cancer therapy. We assess the efficacy of these therapies in terms of tumor response rates, progression-free survival, and overall survival. These findings provide a foundation for evidence-based treatment decisions and shape the future of cancer care^35,36.

6.3 Addressing side effects and safety concerns:

While free radical-based therapies hold great promise, they are not without challenges. This subsection addresses the side effects and safety concerns associated with these therapies. We discuss the mechanisms underlying therapy-induced toxicity and explore strategies to mitigate adverse effects while preserving therapeutic efficacy.

The safety of patients undergoing free radical-based cancer therapy is paramount. By examining the side effect profiles of these treatments and strategies for managing toxicity, we strive to optimize the risk-benefit balance. A nuanced understanding of the challenges in this domain informs clinical decision-making and contributes to the refinement of therapeutic protocols.

Through the exploration of clinical applications and case studies, this section bridges the divide between theory and practice in the realm of free radical-based cancer therapy. It underscores the real-world impact of these therapies, from the laboratory bench to the patient's bedside. By examining both successes and challenges, we gain a comprehensive perspective on the role of free radicals in reshaping the landscape of cancer treatment^36,37.

7. CONCLUSION:

In this comprehensive journey through the intricate realm of free radical-based cancer therapy, we have traversed the landscapes of biology, innovation, and clinical practice. The multifaceted role of free radicals in the complex narrative of cancer has come into focus, revealing both their capacity to promote malignancy and their potential as therapeutic allies. As we reach the culmination of our exploration, this concluding section offers a synthesis of key takeaways and reflections on the present state and future promise of free radical-based cancer therapy.

7.1 Key takeaways:

Throughout this article, we have uncovered the dual nature of free radicals in cancer biology. These highly reactive molecules, while capable of driving oncogenic processes, also impose vulnerabilities within cancer cells that can be exploited for therapeutic benefit. The nuanced interplay between oxidative stress and cancer development underscores the complexity of this disease.

We have explored current strategies for targeting free radicals in cancer therapy, from the use of antioxidants to radiation and chemotherapy approaches. These strategies have demonstrated both successes and challenges, highlighting the need for precision and personalized approaches in treatment.

Additionally, we have ventured into the future of free radical-based cancer therapy, where nanotechnology, gene therapy, and immunomodulatory strategies offer exciting possibilities for innovation. These cutting-edge approaches hold the potential to revolutionize cancer treatment by enhancing specificity, minimizing side effects, and improving patient outcomes ³⁸.

7.2 The promise of free radical-based cancer therapy:

As we conclude this journey, we acknowledge the promise that free radical-based cancer therapy holds for the future. The intricate interplay between free radicals and cancer biology, once viewed as a paradox, has become a source of inspiration for researchers and clinicians alike. Harnessing the potential of free radicals as both foes and allies in the fight against cancer represents a paradigm shift in our approach to this complex disease^38,39.

7.3 The road ahead:

While we have made significant strides in understanding and applying free radical-based cancer therapies, the road ahead is marked by ongoing research, innovation, and clinical integration. Addressing challenges such as treatment toxicity, drug resistance, and patient variability remains essential.

Moreover, the integration of biomarkers and personalized approaches into the therapeutic landscape offers the potential to tailor treatments to the unique biology of each patient and their tumor. Precision medicine, guided by biomarker data and real-time monitoring, heralds a new era in oncology where therapies are finely tuned to maximize efficacy while minimizing harm ³⁹.

In conclusion, free radical-based cancer therapy exemplifies the intersection of scientific discovery, innovation, and clinical practice. The story of free radicals in cancer is one of complexity, contradiction, and possibility. As we continue to unravel the intricacies of this relationship, we embark on a journey where science and humanity converge to redefine the boundaries of cancer care. The future holds the promise of more effective, less toxic, and truly personalized treatments—a testament to the power of knowledge and the resilience of the human spirit in the face of one of our greatest health challenges¹⁸.

8. Future prospects and recommendations:

As we stand at the threshold of a new era in cancer therapy, the future prospects and recommendations for free radical-based approaches in oncology come into sharper focus. This concluding section serves as a compass, guiding us through the uncharted territory of research, clinical practice, and policy, outlining the critical steps needed to realize the full potential of these innovative therapies.

8.1 Shaping the future of free radical-based cancer therapies:

The evolution of cancer therapy is a dynamic process, continually shaped by advancements in science and technology. The future of free radical-based cancer therapies holds great promise, driven by the convergence of multiple disciplines. Here, we delve into the ways in which researchers, clinicians, and policymakers can collaborate to chart a course towards more effective, targeted, and patient-centered treatments.

We discuss the importance of interdisciplinary research, fostering collaborations that bridge the gap between basic science, translational research, and clinical application. By nurturing partnerships across diverse fields, we can accelerate the development of innovative therapies and facilitate their translation into the clinic^4,40.

8.2 Recommendations for further research:

The path forward in free radical-based cancer therapy is illuminated by the questions that remain unanswered. In this subsection, we present recommendations for further research, highlighting areas where continued investigation is essential for advancing our understanding and improving treatment outcomes.

We emphasize the significance of elucidating the precise mechanisms by which free radicals influence cancer biology. Understanding the context-dependent roles of free radicals in different cancer types and stages is crucial for tailoring therapies to specific patient populations. Additionally, exploring the interplay between free radicals and the tumor microenvironment, immune system, and genetic factors offers opportunities for innovative interventions³³.

8.3 Closing thoughts:

In the closing thoughts of this article, we reflect on the remarkable journey through the world of free radical-based cancer therapies. These therapies, once seen as unconventional, have evolved into promising frontiers of cancer research and treatment. Their potential to transform the landscape of oncology is undeniable, offering the prospect of more effective, less toxic, and personalized treatments for patients worldwide.

As we contemplate the road ahead, it is clear that the future of free radical-based cancer therapy is intertwined with the relentless pursuit of knowledge and innovation. By embracing complexity, fostering collaboration, and prioritizing patient-centered care, we can unlock the full potential of these therapies and bring us closer to a future where cancer is a conquerable challenge rather than an insurmountable foe.

9. CONFLICT OF INTEREST:

All others declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content

10. REFERENCES:

1. E. Vignesh Balaji, A. Tamil Selvan. Cancer-A Historical Status, Government Regulation and Current Scenario of Socio-Economic Impact – Retrospective Study. Asian J. Pharm. Res. 2018; 8(3): 133-135 https://doi.org/10.5958/2231-5691.2018.00023.0

2. Akshay R. Yadav, Shrinivas K. Mohite. Cancer- A Silent Killer: An Overview. Asian J. Pharm. Res. 2020; 10(3): 213-216. https://doi.org/10.5958/2231-5691.2020.00036.2

3. Kundan J. Tiwari, Komal Jadhav. Cancer is a Life-Threatening Disease: A Review. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(2): 111-114. https://doi.org/10.5958/0975-4377.2020.00020.8

4. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. European Journal of cancer. 1996; Jan 1; 32(1): 30-8. https://doi.org/10.1016/0959-8049(95)00531-5

5. Martemucci G, Costagliola C, Mariano M, D’andrea L, Napolitano P, D’Alessandro AG. Free radical properties, source and targets, antioxidant consumption and health. Oxygen. 2022; Apr 12; 2(2): 48-78. https://doi.org/10.3390/oxygen2020006

6. Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2015; Jul; 34(28): 3617-26. https://doi.org/10.1038/onc.2014.314

7. Iqbal MJ, Kabeer A, Abbas Z, Siddiqui HA, Calina D, Sharifi-Rad J, Cho WC. Interplay of oxidative stress, cellular communication and signaling pathways in cancer. Cell Communication and Signaling. 2024; Jan 2; 22(1): 7. https://doi.org/10.1186/s12964-023-01398-5

8. Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU. Oxidative stress and its role in cancer. Journal of cancer research and therapeutics. 2021; Jan 1; 17(1): 22-8. https://doi.org/10.4103/jcrt.jcrt_862_16

9. Poprac P, Jomova K, Simunkova M, Kollar V, Rhodes CJ, Valko M. Targeting free radicals in oxidative stress-related human diseases. Trends in pharmacological sciences. 2017; Jul 1; 38(7): 592-607. https://doi.org/10.1016/j.tips.2017.04.005

10. Huang R, Chen H, Liang J, Li Y, Yang J, Luo C, Tang Y, Ding Y, Liu X, Yuan Q, Yu H. Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy. Journal of Cancer. 2021; Jul 25; 12(18): 5543-61.https://doi.org/10.7150/jca.54699

11. Hatta MN, Mohamad Hanif EA, Chin SF, Neoh HM. Pathogens and carcinogenesis: a review. Biology. 2021; Jun 15; 10(6): 533. https://doi.org/10.3390/biology10060533

12. Clemens MR. Free radicals in chemical carcinogenesis. Klinische Wochenschrift. 1991; Dec; 69: 1123-34. https://doi.org/10.1007/BF01645172

13. Cockfield JA, Schafer ZT. Antioxidant defenses: A context-specific vulnerability of cancer cells. Cancers. 2019; Aug 20; 11(8): 1208. https://doi.org/10.3390/cancers11081208

14. Vučetić M, Cormerais Y, Parks SK, Pouysségur J. The central role of amino acids in cancer redox homeostasis: vulnerability points of the cancer redox code. Frontiers in oncology. 2017; Dec 21;7:319. https://doi.org/10.3389/fonc.2017.00319

15. Glasauer A, Chandel NS. Targeting antioxidants for cancer therapy. Biochemical pharmacology. 2014; Nov 1; 92(1): 90-101. https://doi.org/10.1016/j.bcp.2014.07.017

16. Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition. 2013; Jan 1; 29(1): 15-21. https://doi.org/10.1016/j.nut.2012.02.014

17. Ganesh G. Dhakad, Gayatri D. Patil, Ashwini C. Nikum, Sangita P. Shirsat. Review on Radiation Therapy on Cancer. Research Journal of Pharmacology and Pharmacodynamics. 2022; 14(1): 4-2. https://doi.org/10.52711/2321-5836.2022.00002

18. Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, Varol M, Jain A, Khan MA, Sethi G. Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomolecules. 2019; Nov 13; 9(11): 735. https://doi.org/10.3390/biom9110735

19. Kim SJ, Kim HS, Seo YR. Understanding of ROS‐inducing strategy in anticancer therapy. Oxidative medicine and cellular longevity. 2019; 2019(1): 5381692. https://doi.org/10.1155/2019/5381692

20. Lewandowska A, Rudzki B, Brudniak J. Quality of life of cancer patients treated with chemotherapy. International journal of environmental research and public health. 2020; Oct; 17(19): 6938. https://doi.org/10.3390/ijerph17196938

21. Arya B, Krishnaveni K, Sambathkumar R. Review on Antioxidant Supplements use in Cancer Chemotherapy. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(1): 21-24. https://doi.org/10.5958/2321-5836.2020.00005.1

22. Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs. 2011; Jul; 71: 1385-96. https://doi.org/10.2165/11592590-000000000-00000

23. Jalil AT, Abdulhadi MA, Al-Ameer LR, Washeel OF, Abdulameer SJ, Merza M, Abosaooda M, Mahdi AA. Free radical based nano cancer therapy. Journal of Drug Delivery Science and Technology. 2023; Aug 4: 104803. https://doi.org/10.1016/j.jddst.2023.104803

24. Mohd. Yaqub Khan, Brijesh Kumar Saroj, Maryada Roy, Irfan Aziz. A Review- Emerging Use of Nano-Based Carriers in Diagnosis and Treatment of Cancer-Novel Approaches. Asian J. Pharm. Tech. 2015; Vol. 5: Issue 1, Pg 38-49. https://doi.org/10.5958/2231-5713.2015.00008.2

25. Yahya EB, Alqadhi AM. Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sciences. 2021; Mar 15; 269: 119087. https://doi.org/10.1016/j.lfs.2021.119087

26. Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, Neha R. Jaiswal. Review on Gene Therapy on Cancer. Research Journal of Pharmacology and Pharmacodynamics. 2022; 14(1): 37-2. https://doi.org/10.52711/2321-5836.2022.00006

27. Van Loenhout J, Peeters M, Bogaerts A, Smits E, Deben C. Oxidative stress-inducing anticancer therapies: taking a closer look at their immunomodulating effects. Antioxidants. 2020 Nov 27; 9(12): 1188.https://doi.org/10.3390/antiox9121188

28. Alok Kumar, Kanchan Singh, Kartik Kumar, Sachin Kumar, Arjun Singh. Immunotherapy in Cancer Treatment: Harnessing the Power of the Immune System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(1): 107-2. https://doi.org/10.52711/0975-4377.2024.00017

29. Ch. Prudhvi Raju, G. Raveendra Babu, M. Sowjanya, M. Ramayyappa. Evaluation of Cancer Bio-markers through Hyphenated Analytical Techniques. Asian Journal of Pharmaceutical Analysis. 2021; 11(3): 235-2. https://doi.org/10.52711/2231-5675.2021.00041

30. Khan H, Shah MR, Barek J, Malik MI. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry. 2023; Jan 1; 158: 116813. https://doi.org/10.1016/j.trac.2022.116813

31. Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clinical chemistry. 2008; Nov 1; 54(11): 1770-9. https://doi.org/10.1373/clinchem.2008.110056

32. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nature reviews Clinical oncology. 2011; Mar; 8(3): 135-41. https://doi.org/10.1038/nrclinonc.2011.2

33. Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: Current perspectives and new challenges. Ecancermedicalscience. 2019; 13. https://doi.org/10.3332%2Fecancer.2019.961

34. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis. 2017; Nov; 22: 1321-35. https://doi.org/10.1007/s10495-017-1424-9

35. Greenwald P. Clinical trials in cancer prevention: current results and perspectives for the future. The Journal of nutrition. 2004; Dec 1; 134(12): 3507S-12S. https://doi.org/10.1093/jn/134.12.3507S

36. Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, Han J, Wei X. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal transduction and targeted therapy. 2019; Dec 17; 4(1): 62. https://doi.org/10.1038/s41392-019-0095-0

37. C Azoury S, M Straughan D, Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Current cancer drug targets. 2015; Jul 1; 15(6): 452-62. https://doi.org/10.2174/156800961506150805145120

38. Kanti Sahu, Rishita Pathak, Naveen Agrawal, Pinkesh Banjare, Harish Sharma, Gyanesh Sahu. A Review of the Novel Drug Delivery System used in the Treatment of Cancer. Res. J. Pharma. Dosage Forms and Tech. 2019; 11(3): 199-205. https://doi.org/10.5958/0975-4377.2019.00035.1

39. Alok Kumar, Kanchan Singh, Kartik Kumar, Arjun Singh, Alpesh Tripathi, Lakshya Tiwari. Drug Resistance in Cancer Therapy: Mechanisms, Challenges and Strategies. Asian Journal of Nursing Education and Research. 2024; 14(1): 95-0. https://doi.org/10.52711/2349-2996.2024.00019

40. Amy Elizabeth Jaibu, R. Shanmuga Sundaram, Krishnaveni. K, Sambathkumar R. Targeted Cancer Therapy: Promises and Reality. Research J. Pharm. and Tech. 2018; 11(4): 1407-1412. https://doi.org/10.5958/0974-360X.2018.00263.9

Received on 30.07.2024 Revised on 15.11.2024

Accepted on 20.02.2025 Published on 01.07.2025

Available online from July 05, 2025

Research J. Pharmacy and Technology. 2025;18(7):3428-3435.

DOI: 10.52711/0974-360X.2025.00494

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.